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Abstract: Cardiovascular disease remains the most important cause of morbidity and mortality among kidney transplant 
recipients. Nearly half the deaths in transplanted patients are attributed to cardiac causes and almost 5% of these deaths 
occur within the first year after transplantation.  The ideal strategies to screen for coronary artery disease (CAD) in 
chronic kidney disease patients who are evaluated for kidney transplantation (KT) remain controversial. The American 
Society of Transplantation recommends that patients with diabetes, prior history of ischemic heart disease or an abnormal 
ECG, or age 50 years should be considered as high-risk for CAD and referred for a cardiac stress test and only those 
with a positive stress test, for coronary angiography. Despite these recommendations, vast variations exist in the way 
these patients are screened for CAD at different transplant centers. The sensitivity and specificity of noninvasive cardiac 
tests in CKD patients is much lower than that in the general population. This has prompted the use of direct diagnostic 
cardiac catheterization in high-risk patients in several transplant centers despite the risks associated with this invasive 
procedure. No large randomized controlled trials exist to date that address these issues. In this article, we review the 
existing literature with regards to the available data on cardiovascular risk screening and management options in CKD 
patients presenting for kidney transplantation and outline a strategy for approach to these patients. 
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INTRODUCTION 
  Cardiovascular (CV) disease is the leading cause of death 
in patients with chronic kidney disease (CKD). This includes 
patients on dialysis, those wait listed for transplant and those 
with kidney transplantation (KT), and accounts for 42% of 
all deaths in this group [1]. In a study of 23, 546 adult first 
KT recipients in the United States Renal Data System 
between Jan 1995 and Sep 1997, 4.6 % died in the first post 
transplant year, and cardiac causes were the leading cause of 
death, accounting for 27 % of all deaths [2]. Over half of 
these patients die with a functioning allograft, resulting in 
inefficient use of this scarce resource. Therefore, aggressive 
CV risk screening and management before KT has become a 
priority.  
  Though the overall survival is increased by KT, there is 
an initial increase in mortality, soon after KT, and the actual 
survival benefit of KT occurs beyond 250 days of 
transplantation [3]. Hence, it is obvious that patients should 
survive beyond this period in order to be benefited from this 
whole process. CV risk screening for KT is unique in that it 
needs to assess not only the perioperative risk, but also 
should ideally assess the CV risk beyond that period and into 
the early years of transplantation for the above mentioned 
reason. This review will primarily focus on assessing 
coronary artery disease (CAD) risk in pre-KT CKD patients. 
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EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF 
CAD IN PRE-KT PATIENTS 
  CAD is a frequent co morbidity in patients with CKD, 
with a prevalence varying from 24% in young patients 
without diabetes to 85% in elderly hemodialysis patients 
with diabetes [4, 5]. Diabetes is a leading CV risk factor and 
is considered to be a CAD risk equivalent and 40 -50% of 
patients on dialysis are indeed diabetics. Many conventional 
cardiac risk factors such as dyslipidemia, smoking and 
hypertension are less predictive of CAD in renal failure [6]. 
The Framingham risk score underestimates the CV events 
predicted in KT patients [7]. 
  CKD population has additional CV risk related to non 
traditional factors including microalbuminuria, uremia, 
hyperuricemia, calcium – phosphorus disorder associated 
calcification, inflammation and hyperhomocysteinemia. Pre-
KT CV risk factors often persist after KT and can worsen in 
the post transplantation period resulting in accelerated 
atherosclerosis. Anti rejection therapy used in the post 
transplant period such as steroids, calcineurin inhibitors and 
sirolimus increase the development of or worsening of 
preexisting hypertension, dyslipidemia, hyperuricemia, 
weight gain and glucose intolerance. All these factors make 
KT candidates a unique population that may require a 
different CV risk screening strategy as well as management. 
CLINICAL PREDICTORS OF CAD IN KT 
CANDIDATES 
  Presence or absence of chest pain does not correlate well 
with CAD in CKD patients [8]. Severe CAD is common in 
asymptomatic patients with CKD, likely because of 
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Braun et al. [9] reported that up to 75% of the patients with 
CAD undergoing hemodialysis did not have typical angina, 
making silent CAD three times more prevalent than in the 
Framingham study population [10]. A large proportion of 
these patients lead a sedentary lifestyle as a result of reduced 
exercise capacity which also contributes to the lack of 
symptoms. The reduced exercise capacity is a result of 
muscle fatigue, anemia and a generalized feeling of being ill 
after dialysis likely secondary to rapid fluid and electrolyte 
shifts. As a result, a good proportion of patients live with 
functional status below 4 METS, making assessment on 
clinical grounds difficult. The converse, which is angina 
without CAD on angiography has also been reported to 
occur in up to 50% of all patients [11, 12]. Reasons for 
symptoms in the absence of epicardial CAD include anemia, 
reduced vasodilator reserve, microvascular disease and 
supply demand mismatch resulting from severe left 
ventricular hypertrophy (LVH) that is seen in about 70 % of 
patients with CKD [13]. LVH can lead to increased oxygen 
demand and subsequently to angina, even in the presence of 
normal coronary arteries. Rostand et al. [11] showed that 
27% of dialysis patients who presented with angina did not 
have evidence of CAD on angiography [14]. The sensitivity 
and specificity of angina for predicting angiographic CAD 
was 65% and 66% respectively, and all patients with angina 
but no major epicardial CAD had LVH [14]. For all these 
reasons, chest pain has poor sensitivity and specificity for 
predicting CAD in CKD patients. 
 Gowdak  et al. [15] sought to determine clinical 
predictors of significant CAD (coronary stenosis  70%) in 
high-risk KT candidates. Clinical evaluation and coronary 
angiography (CA) were performed in 301 hemodialysis 
patients with diabetes (type 1 or 2), evidence of CV disease, 
or age 50 years and they were followed-up for 22 months 
(median). Of all the risk factors studied, prior MI, peripheral 
vascular disease (PVD) and diabetes were significantly 
associated with angiographic CAD and future clinical events. 
They noted a direct relationship between these clinical 
variables and the prevalence of significant CAD. When all 3 
risk factors were present, the prevalence of CAD (> 70 % 
stenosis) was 100%, compared to 25.7%, in those in whom 
all three factors were absent. The study selected out and 
identified patients in whom the benefit of CA may outweigh 
the risks of the procedure. This model also favors non 
invasive testing in patients with no major risk factors which 
helps to avoid indiscriminate use of CA. These clinical 
variables not only predicted CA stenosis > 70%, but also 
fatal and nonfatal CV events. Compared to those with no 
clinical predictors, the composite incidence of fatal and 
nonfatal CV events was twofold higher in patients with 
diabetes, fourfold in patients with PVD, and sixfold in 
patients with previous MI. Similarly, incidence of CV 
mortality was increased threefold in patients with diabetes, 
sixfold in those with PVD, and threefold in patients with a 
history of MI. They also found that risk analysis has similar 
sensitivity (80%) and negative predictive value (NPV) as CA 
in predicting cardiac events.
CARDIAC SCREENING FOR KT: AN OVERVIEW 
  Conflicting data exists on the best method of cardiac 
screening and risk stratifying KT candidates. Some studies 
have suggested that CA may be the best screening method 
[16]. Other studies have shown that simple clinical risk 
stratification as well as non invasive testing such as with 
stress single photon emission computed tomography 
(SPECT) can accurately predict perioperative and post 
transplant cardiac events [17]. Furthermore a meta analysis 
of myocardial perfusion imaging studies in CKD patients 
[18] showed that an ischemic study predicted a sixfold 
increase in MI and fourfold risk of death. Fixed defects were 
also predictive of increased cardiac death. As with other 
stress tests a negative perfusion imaging study carries more 
favorable prognostic value in predicting lower perioperative 
cardiac events.
  Dobutamine stress echocardiography (DSE) has also 
been studied in this population, but found to have a wide 
range of sensitivities from 38 to 95% and specificity from 71 
to 96% [19, 20]. The differences in the results in these 
studies are likely related to the differences in the study 
population, small sample sizes and lack of prospective 
randomized design, and differences in the medical therapy of 
CAD instituted successfully. 
  The American College of Cardiology/American Heart 
Association (ACC/AHA) guidelines for perioperative 
evaluation and management has been revised and published 
in 2007 [19]. The Revised Cardiac Risk Index published by 
Lee et al. [21] is considered the preferred clinical risk 
assessment tool to identify patients who may require 
additional evaluation. Renal insufficiency is part of this risk 
index and has been highlighted as a cardiac risk factor in the 
recent guidelines. Interestingly no specific recommendations 
regarding risk stratification strategies for pre-KT assessment 
are made reflecting lack of well designed studies. 
  Guidelines for cardiac screening in KT candidates are 
largely based on data from the non uremic population. The 
ACC/AHA perioperative assessment guidelines [19] suggest 
that patients with > 3 clinical risk factors and/or poor 
functional capacity (< 4 METS equivalent activity level) 
being evaluated for vascular surgery can be screened using 
noninvasive cardiac testing (class 11a). Those with 1-2 
clinical risk factors and/or poor functional capacity going for 
intermediate-risk non-cardiac surgery may be considered for 
noninvasive testing (Class11b). The American Society of 
Transplantation recommends [22] that patients at high risk, 
e.g. renal disease from diabetes, prior history of CAD, or 2
risk factors, should have a cardiac stress test. Risk factors 
included here are: a prior history of CAD, men 45 or 
women  55 years, CAD in a first degree relative, current 
cigarette smoking, diabetes, hypertension, fasting total 
cholesterol > 200 mg/dl, high density lipoprotein cholesterol 
< 35 mg/dl and LVH. These guidelines recommend that 
those with positive cardiac stress test should undergo CA 
[23]. The sensitivity and specificity of non-invasive tests in 
pre-KT CKD patients is lower than that in the general 
population [16, 24, 25]. Some transplant centers have 
adopted a policy of direct diagnostic CA in high risk 
patients, despite the absence of convincing evidence to 
support routine invasive stratification.  
  In addition to the unanswered questions regarding the 
initial screening strategy for CAD in KT candidates, there 
are also uncertainties regarding periodic screening of wait 
listed patients. A patient may have minimal CAD at the time Coronary Risk Assessment and Management Options  Current Cardiology Reviews, 2009, Vol. 5, No. 3    179
of initial evaluation, but then develop significant disease 
while waiting on the KT list. Since CKD is associated with 
activation of systemic inflammation and increased oxidative 
stress, this sets the stage for accelerated atherosclerosis seen 
in this patient group [26]. It is not clear how frequently to re-
test them, whether re-testing is of value or is periodic clinical 
evaluation sufficient. No randomized controlled trials exist 
to date addressing all these issues.
NON INVASIVE CARDIAC EVALUATION IN PRE-
KT CKD PATIENTS: A COMPARATIVE OUTLOOK 
OF DIFFERENT METHODOLOGIES 
a. Electrocardiogram (EKG)/Exercise Electrocardio-
graphy (Treadmill) 
  An abnormal EKG is very common in CKD patients and 
was found in 46% of patients in one study [8]. Voltage 
criteria for LVH, T wave changes and bundle branch blocks 
account for most of the baseline abnormalities. This high 
prevalence of abnormal baseline EKG in renal failure has 
been described by several authors [27, 28] and is thought to 
be due to LVH, volume overload and electrolyte 
abnormalities typically seen in CKD patients. Baseline EKG 
abnormalities are much rarer in the general population, 
occurring in only 8.5% of men and 7.7% of women [29]. 
Sharma  et al. [8] found abnormal baseline EKG to be an 
independent predictor of angiographically proven CAD in 
125 KT candidates all of whom underwent CA. Its 
sensitivity was 77% but specificity only 58%. Exercise EKG 
was not predictive of CAD in this group of patients [8]. 
Others authors found that neither resting nor exercise EKG 
was predictive of CAD [14]. Because of the high prevalence 
of non specific abnormalities in baseline EKG and the 
conflicting literature on its usefulness, neither resting nor 
exercise EKG is accepted as a useful screening tool in KT 
candidates undergoing cardiac evaluation. 
b. Cardiac Single Photon Emission Computed Tomo-
graphy (SPECT) 
  The sensitivity and specificity of non invasive tests to 
detect CAD in CKD patients are highly variable and are 
often below 70% [14, 30]. Marwick et al. used a control 
group in their study showed that the sensitivity of 
dipyridamole thallium scintigraphy for detecting CAD was 
95 % in control group but only 37% in dialysis patients with 
a modest specificity of 73% using a 50% stenosis detection 
on CA [25]. Using a quantitative CA lesion severity 
definition of 70% cross sectional narrowing, Boudreau et al. 
[31] reported 86% sensitivity and 72% specificity for 
intravenous dipyridamole planar thallium. Vandenberg et al. 
[24] retrospectively compared pharmacologic stress thallium 
scintigraphy with CA and demonstrated 53% sensitivity and 
73% specificity compared with a visually estimated stenosis 
of 50% or greater and 62% sensitivity and 76% specificity 
for stenosis of 75% or greater. The lower sensitivity in CKD 
population has been attributed to several factors. CKD 
patients have higher levels of basal adenosine resulting in a 
high resting coronary flow. Pharmacologic myocardial 
perfusion imaging uses dipyridamole (which works by 
increasing endogenous adenosine levels) or adenosine as 
vasodilator to induce stress by challenging the flow reserve. 
The higher resting blood flow in CKD patients blunts the 
flow reserve challenge and thus can compromise the sensi-
tivity of SPECT imaging by decreasing heterogeneity of 
radioisotope uptake which forms the basis of detection of 
CAD by this modality [25]. Also many pre-KT patients are 
on multiple anti-hypertensive’s, many of which are also anti-
anginals (beta-blockers, calcium blockers, nitrates). These 
agents are known to decrease sensitivity of stress SPECT 
imaging [32, 33] by reducing ischemic burden. Despite these 
limitations, SPECT imaging has been recently shown to 
provide useful information for pre-KT risk assessment. Patel 
et al. [34] studied 600 patients undergoing pre-KT evalua-
tion and among these 174 had SPECT imaging done. In 
these patients adverse outcomes were predicted by an 
abnormal SPECT (the only multivariate predictor) whereas 
event free survival was 97% in patients with a normal 
SPECT over a 42 month follow-up period. Thus, a negative 
SPECT carries a very favorable prognostic value in the short 
and long term prediction of low cardiac events used as an 
endpoint. A positive SPECT also carries adverse outcomes 
and warrants aggressive medical therapy and consideration 
of revascularization if ischemic burden is high.
c. Dobutamine Stress Echocardiography (DSE) 
  DSE is a well established modality for detection and 
prognostication of CAD [35]. Prior studies have shown 
consistently the excellent negative predictive value of a 
normal DSE in patients undergoing major surgery [36, 37]. 
 De  Lima  et al. [16] prospectively studied KT candidates 
subjecting them to CA, clinical risk stratification and 2 non 
invasive modalities of testing - DSE and dipyridamole 
SPECT with tech 99 MIBI, and followed them for a mean of 
26 months for cardiac events. Patients were chosen based on 
the presence of at least one risk factor: age  50 years, DM, 
angina, prior MI or stroke, LV dysfunction or extra cardiac 
atherosclerosis. One hundred and twenty six patients 
underwent one or more of the 3 tests and 88 patients 
underwent all 3 tests. The results of the non invasive tests 
and clinical risk stratification correlated significantly with 
the degree of CAD, defined in this study as  70 % coronary 
stenosis by visual estimation. However, 30% of patients with 
negative results on both non invasive studies had critical 
coronary stenosis on CA. The sensitivities of DSE, SPECT 
and clinical risk stratification were low, between 35 and 
64%, NPV < 70%. DSE and SPECT results did not predict 
future cardiac events. Simple clinical risk stratification was 
able to better predict future cardiac events than the two non 
invasive tests in this study.  
 Reis  et al. [38] also studied DSE in KT candidates and 
used only fatal events as end points during a follow-up 
period of 12 ± 6 months. Twenty-nine of 97 patients studied 
had inducible ischemia by DSE (30%). DSE had a positive 
predictive value of 14% and a negative predictive value of 
97% for 1-year survival indicating the more robust predictive 
value for a normal DSE. On the other hand, several studies 
have found DSE to be able predict CAD in KT candidates 
[20]. A positive DSE has been identified as an independent 
predictor of severe CAD [8, 20]. Herzog et al. [20] compared 
DSE and CA in 50 patients evaluated for KT. The sensitivity 
and specificity of DSE was tested for detection of quanti-
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and qualitative visual estimation for stenosis > 75%. Twenty 
of 50 DSE tests were positive for inducible ischemia. The 
sensitivity and specificity of DSE for CAD diagnosis were 
respectively 52% and 74% for QCA stenosis of  50%, 75% 
and 71% for QCA stenosis greater than 70%, and 75% and 
76% for stenosis greater than 75% by visual estimate. On 
long-term follow-up (22.5 ± 10.1 months), 6 of 30 patients 
(20%) with negative DSE results and 11 of 20 patients (55%) 
with positive DSE results had a cardiac death, MI, or 
coronary revascularization. During a mean follow of 22 
months, for the combined end points of cardiac death, MI, or 
coronary revascularization, a positive DSE result was 
associated with significantly worse event-free survival. The 
event rate in positive and negative DSE results was 55 % and 
20% respectively. In this study, a positive DSE was 
associated with angiographic CAD and future cardiac events. 
More importantly, a normal DSE predicted event free 
survival even in those with angiographic CAD. Others such 
as Bates et al. [39] have also reported prognostication with 
DSE in that 9 of 20 patients (45%) with a positive DSE and 
2 of 33 patients (6%) with a negative DSE had a cardiac 
event in a follow-up period of 813 ± 395 days, a statistically 
significant difference.
  More recently the role of DSE in cardiac risk 
stratification was evaluated by the us (authors) at our 
institution in a retrospective study of 149 patients who 
underwent DSE prior to KT [40]. This study conducted on a 
predominant African American population again showed that 
DSE had 37.5% sensitivity, 95.3% specificity, 33.3% 
positive predictive value, and 96.1% negative predictive 
value for major cardiac events in the first year after KT. 
First-year post transplant event rates were 4.0% versus 30% 
(P < 0.001) for patients with negative and positive stress 
echo, respectively. This remained true regardless of the need 
for revascularization procedures, as shown in our study 
where among the 12 patients who were subjected to CA (all 
10 patients with positive DSE and 2 others with very sub 
maximal stress levels), only one patient needed revasculari-
zation. This reemphasizes the importance of non-occlusive 
atheromata as being important targets for aggressive medical 
therapy and plaque stabilization. A positive DSE thus 
identifies a high risk group of individuals who regardless of 
CA results have increased cardiac events.  
  In general DSE is more specific than SPECT for CAD 
diagnosis as it uses ischemia as the endpoint of CAD 
compared to flow heterogeneity in SPECT which renders the 
latter more sensitive but less specific. But DSE has its 
limitations in that presence of underlying LVH with resultant 
small intra cavitary volume occurring at peak dobutamine 
stress that may obscure the detection of minor wall motion 
abnormalities [41]. In particular, concentric remodeling of 
the left ventricle was found to be the most frequent cause of 
false negative results with DSE in one study [42]. It is felt 
that blunted rise in end-systolic wall stress may be one of the 
mechanisms for this underestimation of CAD. Another 
reason for a false negative DSE is lack of achievement of 
target heart rate responses. Although the prognostic 
implications regarding sub-maximal DSE has been 
conflicting with some studies suggesting adverse outcomes 
[43, 44] and others favorable outcomes, [45], below target 
heart rates can decrease detection of anatomical CAD. In this 
regard, CKD patients have most of the characteristics which 
may decrease the sensitivity of DSE for CAD detection. 
They have a high incidence of HTN, LVH and also a high 
incidence of sub maximal heart rates during DSE [40]. Thus, 
all of these factors need to be kept in mind when utilizing 
and interpreting DSE in CKD patients.
d. Coronary Angiography (CA) 
  CA being an invasive procedure, the benefits have to be 
weighed against the risk in any individual. Some authors 
advocate CA in all high risk CKD patients, particularly 
diabetics being evaluated for KT. In a study by Sharma   
et al., of 125 renal transplant candidates who underwent CA 
[8], 44% of diabetics had severe CAD, defined as luminal 
stenosis >70% by visual estimation in at least one epicardial 
artery and mortality was significantly higher in this group. 
However, only 20% of non-diabetics had severe CAD. 
Overall, 36/125 patients had >70% stenosis, but only 15/125 
(12%) underwent revascularization and CA did not lead to 
active intervention in 88% of patients. To date, there is only 
one randomized prospective study assessing revasculariza-
tion vs. medical therapy in KT candidates done in early 
1990’s. Manske et al. [46] subjected 151 consecutive asymp-
tomatic insulin-dependent diabetic KT candidates to CA. 
Thirty one patients had at least one coronary artery stenosis 
greater than 75%. Patients with angina or a left ventricular 
ejection fraction below 35% and significant three-vessel 
disease were excluded. Patients with coronary artery lesions 
judged to be hemodynamically significant and suitable for 
revascularization, were then randomized to 2 strategies.
Twenty six were randomized to either medical therapy (13 
patients), consisting of calcium channel blockers (CCB) and 
aspirin vs. revascularization (13 patients). Ten of 13 medi-
cally managed and 2 of 13 revascularized patients had a 
cardiovascular endpoint within a median of 8.4 months of 
coronary angiography. They concluded that revascularization 
of angiographically significant coronary artery stenoses in 
asymptomatic diabetic KT candidates may decrease the 
incidence of cardiac events. This study does not address the 
issue of which test will be ideal to detect CAD, as no 
noninvasive testing was done. Although it supports 
revascularization in these patients with significant CAD, it 
does not support doing routine CA in all KT candidates. 
Only 31 out of 151 (20.5%) had stenosis > 75% in this study 
by CA. Nearly 80% had insignificant CAD and therefore 
unnecessary CA. Uniform medical treatment between the 
two groups could not be confirmed. Also, CCB were used as 
anti ischemic therapy, not betablockers for fear of 
aggravating hypo-glycemic unawareness. Statins were not 
used in all patients and current aggressive medical therapy 
for stable CAD as shown in the COURAGE trial [46] was 
not done at that time. It is possible that the medical therapy 
group would have done better with betablockers and high 
dose statins. Finally this trial focused on diabetics and is not 
applicable to non-diabetic CKD patients. Subsequent to this 
trial there are no published randomized data in over a decade 
comparing pre-KT CKD patients on aggressive medical 
regimen (aspirin, betablockers, statins) to revascularization 
strategies. 
   More recent studies have addressed whether pre surgical 
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other major surgeries. The Coronary Artery Revasculariza-
tion Project (CARP) [47] randomized patients with greater 
than 70% coronary stenosis who were scheduled to undergo 
elective vascular surgery, to coronary revascularization vs. 
no revascularization. No difference in primary outcome 
(mortality) or secondary outcome measures (MI, stroke, 
renal failure, and limb loss) were seen during the follow up 
period. This is the first and largest randomized trial to date 
showing that routine revascularization prior to major 
vascular surgery was not associated with improved out-
comes. The DECREASE-V pilot randomized study [48] 
looked at noninvasive versus prophylactic revascularizations 
strategies in patients with 3 vessel CAD undergoing major 
vascular surgery. It showed no advantage of prophylactic 
revascularization in patients with stable CAD with com-
posite endpoint of all-cause mortality and MI at 30 days and 
1 year. It is important to note that both these trials were 
underpowered for outcomes. Nevertheless the 2007 ACC 
/AHA guidelines have also recommended that prophylactic 
revascularization is not warranted prior to non-cardiac 
surgery in stable CAD patients. The ACC/AHA perio-
perative guidelines and the results of these 3 trials (CARP, 
COURAGE and DECREASE –V)(11,43-45) reemphasize 
that aggressive medical therapy for stable CAD is a very 
viable option in the perioperative setting.  
  Can the ACC/AHA peri-operative assessment guidelines 
and the results of the above trials be applied to pre-KT 
assessment? The answer is “not clear” and the authors 
believe that evidence from existing guidelines cannot be 
readily extrapolated to KT candidates for the following 
reasons: In the general population the preoperative and 
postoperative risk are not significantly altered as a sequelae 
of surgery. However following KT, patients are exposed to a 
postoperative milieu that promotes development or 
worsening of accelerated atherosclerosis both due to 
presence of persistent abnormal renal function [49] and the 
adverse effect of immunosuppressive drugs [49]. Thus, 
uncorrected and unrecognized CAD could get worse after 
KT leading to complications including fatal CV events, 
wasting a valuable and limited resource, the transplanted 
kidney [2]. Furthermore, subjecting patients to CA soon after 
KT carries the risk of exposure of transplanted kidney to 
radiocontrast dye with risk of worsening renal function. Thus 
addressing significant CAD prior to KT may carry a dual 
advantage of avoiding cardiac morbidity and mortality and 
preventing CA after KT. Most centers involved in KT follow 
the AST guidelines which is to perform a noninvasive 
screening test in those with cardiac risk factors and CA is 
reserved for patients with abnormal stress test results. 
Although some centers perform routine CA, there is no 
convincing evidence that routine CA is justified in all KT 
candidates, as only a minority of these diagnostic catheteri-
zations lead to any revascularization in the pre-KT CKD 
patient [8, 40]. Furthermore contrast nephropathy, defined as 
a serum creatinine increase of greater than 25% when 
measured 48 hours after radiocontrast exposure, can occur in 
up to 50% of azotemic diabetic patients undergoing CA [50]. 
Careful thought and discussion with the pre-KT patient is 
needed prior to CA particularly when using it as a screening 
test. The good news is that the risk of loss of any residual 
renal function in patients on peritoneal dialysis, undergoing 
coronary angiography has been studied prospectively [51] 
and retrospectively [52] and appears to be quite small. No 
accelerated decline in renal function was noted in stable 
peritoneal dialysis patients. So adopting an initial non-
invasive strategy followed by CA as deemed necessary may 
avoid unnecessary exposure to invasive procedures and 
contrast. 
e. Coronary Computed Tomography Angiography 
(CCTA) 
  It is well known that CKD patients, particularly those on 
hemodialysis have a higher burden of coronary calcification 
than the general population [53]. This along with the concern 
of exposing CKD patients to radiocontrast dye has essen-
tially excluded these patients from CCTA studies. To our 
knowledge there is no published study employing CCTA to 
evaluate CAD in CKD patients on dialysis. All data using 
CCTA in advanced CKD patients are limited to calcium 
burden assessment which is a non-contrast procedure. 
Preliminary data has just been published in abstract form by 
our group testing the Safety, Feasibility and Interpretability 
of CCTA in pre-KT patients on hemodialysis or peritoneal 
dialysis [54]. This study looked at 28 patients on dialysis 
undergoing cardiac risk assessment before KT. Interestingly 
35% of patients had a zero calcium score and interpretability 
was excellent for conclusively excluding significant 
proximal-mid coronary disease in all 3 vessels and in the left 
main territory. Furthermore CCTA was able to conclusively 
exclude significant CAD in 7/11 patients with a submaximal 
dobutamine echo thus avoiding another stress test or CA. 
CCTA was well tolerated by all patients and there were no 
study related complications. Further studies are needed to 
evaluate if a certain subgroup of CKD patients on dialysis 
can be offered CCTA as a noninvasive screening tool for 
CAD. 
MANAGEMENT STRATEGIES IN THE PRE-KT CKD 
PATIENT  
Medical Therapy  
  There is sparse literature focusing on specific medical 
therapy to optimize and reduce perioperative risk in CKD 
patients going for KT. Most of the cardiac protective 
therapies such as aspirin, betablockers and statins used in the 
perioperative period are based on evidence from the general 
population studies. Since CKD is considered a coronary risk 
equivalent and is associated with multiple cardiac risk 
factors, use of these agents may seem a rational approach but 
has so far not been well studied. We will focus on three of 
the most common medication strategies employed for 
reducing cardiac risk, namely aspirin, betablockers and 
statins. 
Aspirin  
  The role of aspirin in preventing atherothrombotic events 
in high risk patients is known [55, 56]. However its role in 
primary cardiac event prevention strategy in CKD patients 
has not been conclusively demonstrated. Haemostatic 
abnormalities and uremic platelet dysfunction increase as 
kidney function declines. Thus possible benefits of anti-
platelet therapy may be offset by a higher absolute risk of 
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anti-platelet trial meta analysis [55] 46 bleeds occurred but 
not of sufficient number to demonstrate a risk. In favor of 
aspirin a 41% reduction in MI, stroke and vascular deaths 
were noted. The United Kingdom Heart and Renal 
Protection placebo controlled study [59] tested the safety and 
efficacy of simvastatin 20 mg daily and 100 mg /day of 
modified release aspirin in 448 predialysis, dialysis and KT 
patients. There was a threefold increase in minor bleeds but 
no statistically significant increase in major bleeds. In 
summary, although the risk of atherosclerotic disease in 
CKD patients would suggest aspirin as being a beneficial 
strategy for primary prevention, randomized trials are 
lacking for this and the concern for bleeding exists. Thus this 
risk should be discussed with the patient prior to initiation of 
aspirin for primary prevention. In pre-KT patients with 
established CAD, prior MI, stroke or PVD low dose aspirin 
(81mg/day) should be used as benefits outweigh risks. The 
evidence for use of clopidogrel is lacking for both primary 
and secondary prevention of atherosclerotic disease in CKD 
and hence should be reserved for standard indications where 
combination antiplatelet therapy may be needed (i.e.: post 
stent implantation) or when patients are aspirin intolerant. 
Betablockers 
  The main premise for prescribing betablockers in the 
peri-operative period is to establish a favorable balance of 
myocardial oxygen supply-demand. Although prior studies 
have demonstrated beneficial effects [60-62] more recent 
studies have suggested no benefit [63, 64] with one 
indicating increasing mortality (POISE trial) [63]. The use of 
cardio protective medications is also uncommon in pre-KT 
CKD patients and only 20 to 45% of high-risk patients 
received either angiotensin-converting enzyme inhibitors 
(ACEI), betablockers, or lipid-lowering medications at the 
time of wait-listing [8]. More disappointing is that
betablockers and ACEI are not used significantly more often 
even in those CKD patients with CAD [8].
  It is also still unclear which beta blocker should be used, 
when they should be initiated and how long they should be 
continued. There may be two facets to consider when using 
betablockers in KT candidates: 1. an acute effect on 
myocardial oxygen demand, heart rate and blood pressure 
brought about by initiation hours prior to surgery and 2. 
longer term plaque stabilizing effect when started days prior 
to surgery. In particular the DECREASE –I trial started 
bisoprolol (longer half-life) an average of 37 days prior to 
surgery with careful up titration and was associated with a 
tenfold decrease in perioperative events [61]. This is in 
contrast to the POISE trial which gave high dose controlled 
release metoprolol just prior to surgery with maximum doses 
of 400 mg achieved 1 day after surgery. POISE showed that 
although cardiovascular events were decreased by beta-
blockers, overall mortality was increased likely due to a 
higher incidence of ischemic stroke. Thus, although no 
particular beta blocker/regimen can be specifically recom-
mended at this time, we suggest that KT candidates be 
treated by the strategy based on the ACC/AHA guidelines 
(11): 1. Betablockers should probably be initiated if possible 
in all patients as they have a higher risk for atherosclerosis, 
more importantly if they have a positive stress test. 2. 
Patients on betablockers should continue on it. 3. Tight heart 
rate control (HR 60-65 beats per minute) in the perioperative 
period be done to decrease cardiac events. 4. Betablockers 
should be started at least 1-3 weeks prior to surgery and up 
titrated to get adequate heart rate control (HR< 65). We 
recommend that they be continued in the perioperative 
period given beneficial effects on long term outcomes [60] 
and because abrupt discontinuation can be associated with 
increased adverse outcomes [65].
Statins  
  Although CKD patients on hemodialysis have a high CV 
morbidity and mortality the evidence for lipid lowering 
agents in modulating this risk is at best equivocal. Initial 
observational data favoring reduction in CV and total 
mortality with statin therapy has been published [66, 67] but 
subsequent studies have not been positive. There are several 
reasons as to why lowering LDL cholesterol may not be as 
beneficial in advanced CKD patients. In dialysis patients a 
negative association has been demonstrated between 
cholesterol and mortality [68, 69]. Only approximately one 
quarter of the cardiac mortality in CKD is attributable to 
acute MI [70]. This was shown in the 4D study which 
evaluated 1255 Type 2 diabetics on hemodialysis and 
randomized them to 20 mg atorvastatin or placebo [71]. In 
contrast to the observational data [66, 67] this study showed 
no significant difference in composite endpoint of CV death, 
nonfatal MI or stroke. Concerning was that atorvastatin 
seemed to increase the risk for fatal stroke. A significant 
proportion of the deaths were actually attributed to sudden 
cardiac death in both groups (59% of deaths) suggesting that 
death may be driven by dysrhythmia not modifiable by 
statins. Other non-statin agents have also been studied. The 
OPACH trial was a randomized double-blind placebo 
controlled trial testing 206 hemodialysis patients with either 
1.7 grams/day of omega-3 fatty acids or an olive oil placebo. 
Although primary endpoint of CV events or death was non 
significant, a 70% reduction in MI was noted [72].  
  The role of statins in advanced CKD patients may be 
better clarified by 2 ongoing trials, one in 2700 hemodialysis 
patients, testing 10mg of rosuvastatin versus placebo (the 
AURORA study) [73], and the other, Study of Renal and 
Heart Protection (SHARP) one arm of which is comparing 
20 mg of simvastatin to 20mg of simvastatin plus eztemibe 
in 3000 hemodialysis patients [59]. Until then, given the CV 
risk profile of CKD patients we believe the following 
approaches could be considered. 1. For patients with 
documented CAD, statins should be initiated to attain target 
LDL levels of < 70 mg/dl. 2. In CKD patients with no known 
CAD, statins should be strongly considered if LDL > 100, 
and targeted to less than 100 mg /dl. 3. For CKD patients 
with LDL levels < 100 mg/dl, if CAD or other 
atherosclerotic vascular disease is present or if ischemia is 
detected on stress testing, low dose statins can be initiated 
given pleiotropic effects of statins on plaque stabilization 
and atherosclerotic vascular disease mitigation independent 
of LDL lowering [74, 75]. Since this manuscript primarily 
focuses on CKD patients, statins with limited renal 
excretions such as atorvastatin and fluvasatin may be good 
initial choices. Combination therapy with fibrates needs to 
avoided as they are metabolized through the kidney and are 
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m. by the National Lipid Association. If triglycerides are 
high, omega-3 fatty acids 3-4 grams /day can be used. 
Coronary Revascularization  
  When revascularization is contemplated in a KT 
candidate with significant CAD, several important issues 
need to be addressed. If percutaneous coronary revasculari-
zation is planned, it may warrant use of drug eluting stents to 
reduce re-stenosis in this high risk population. The use of 
drug eluting stents poses a problem if a patient is to be listed 
for KT as clopidogrel and aspirin therapy are currently 
recommended to be continued uninterrupted for at least one 
year and maybe longer after the intervention [19]. Premature 
interruption of these agents for elective KT poses 
unnecessary risk of acute stent thrombosis and MI which is 
deleterious to the transplanted kidney and disastrous for the 
patient as mortality rates are high. Thus when PCI is 
contemplated, consideration for bare metal stents (requiring 
only 30-45 days of uninterrupted dual anti-platelet therapy 
with subsequent option of clopidogrel discontinuation), or 
plain old balloon angioplasty should be considered. If 
anatomy is suitable for bypass surgery this option should be 
discussed with the patient. In our institution as part of pre 
CA discussion the CKD patient and nephrologist are made 
aware that if a drug eluting stent is placed the patient will be 
off the KT waiting list at least for 1 year and then reevalua-
ted by cardiology prior to relisting. Aspirin is recommended 
to be continued uninterrupted even during KT if clopidogrel 
is stopped.  
  In summary after review of all available evidence and 
based on our institutional experience we have outlined an 
algorithm of how to approach a KT candidate with regards to 
coronary risk assessment (Fig. 1). 
CONCLUSION 
  Well designed prospective randomized trials are urgently 
needed to identify the best cardiac screening modality in KT 
candidates with low, intermediate and high clinical risk 
profiles. Specific guidelines are needed to regulate the 
management of CV risk factors both before and after KT. 
Ideally this should be based on strong medical evidence with 
randomized controlled trials. Ongoing intervention programs 
are needed to treat hypertension, diabetes and dyslipidemia 
until the goals are met. Lifestyle changes including smoking 
cessation, weight reduction and physical activity need to be 
emphasized regularly. 
Fig. (1). Proposed algorithm outlining cardiac risk stratification approach in pre –KT patients. (KT= kidney transplant). 184 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Karthikeyan and Ananthasubramaniam 
  Based on available evidence, all patients with any of the 
following risk factors - age 50 years, angina, diabetes, prior 
CVA, MI or PVD should be considered candidates for non 
invasive cardiac screening regardless of symptoms. Lower 
threshold for screening may be needed while dealing with 
patients with low functional capacity (< 4 METS). No 
adequate data are available at this time for recommendations 
for CV screening solely based on non traditional risk factors 
in this group, i.e. hyperhomocys-teinemia, hyperuricemia, 
high calcium phosphorus product, high C reactive protein. 
DSE can be an ideal initial screening modality in the absence 
of contraindications as it also provides assessment of the 
cardiac chambers, valves and LVH. It is important that 
adequate stress levels are reached to avoid false negative 
results. Holding betablockers for 24 hours prior to testing if 
not contraindicated can improve the ability to achieve target 
heart rate. Incomplete tests due to severe hypertensive 
response or submaximal heart rates need to be followed by 
other tests (e.g. adenosine nuclear or CA). Lower threshold 
to do CA is needed in patients with low LVEF to diagnose 
ischemia as the cause of decreased LVEF. 
  CV risk screening for KT is unique in that it needs to 
assess not only the perioperative risk, but also should ideally 
assess the CV risk beyond that period and into the early 
years of transplantation in order for these patients to benefit 
from the whole process. As revascularizable disease remains 
under 10-15% in most series performing CA, despite the 
high cardiac events and mortality in this group, the answer 
may very well lie in life style modification, risk reduction 
and aggressive medical therapy until pre defined goals are 
met. 
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